Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916032 | 0.88 | CYP2D6 (0.42) | KMT2AMEN1ALDH1A1CYP2D6 | |
| SCHEMBL3925382 | 0.87 | ALDH1A1 (0.51) | EPHX2KMT2AMEN1ALDH1A1CYP2D6 | |
| SCHEMBL3925389 | 0.86 | ACLY (0.35) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL3925468 | 0.86 | MMP2 (0.37) | KMT2AMEN1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4038204 | 0.84 | EPHX2 (0.47) | EPHX2EBPDHCR7CCR5KMT2A | |
| SCHEMBL3916725 | 0.83 | KMT2A (0.40) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL3918973 | 0.83 | L3MBTL1 (0.46) | EPHX2KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3918975 | 0.83 | L3MBTL1 (0.46) | EPHX2KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3917715 | 0.83 | RAB9A (0.44) | EPHX2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3917062 | 0.83 | CHRM5 (0.46) | KMT2AMEN1ALDH1A1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | claimed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | EPHX2 4355/4885EBP 919/4885DHCR7 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.